| Heme oxygenase-1 inhibits myoblast differentiation by targeting myomirs M Kozakowska, M Ciesla, A Stefanska, K Skrzypek, H Was, A Jazwa, ... Antioxidants & redox signaling 16 (2), 113-127, 2012 | 134 | 2012 |
| Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities K Lemke, M Wojciechowski, W Laine, C Bailly, P Colson, M Baginski, ... Nucleic acids research 33 (18), 6034-6047, 2005 | 62 | 2005 |
| C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells EE Bram, I Ifergan, M Grimberg, K Lemke, A Skladanowski, YG Assaraf Biochemical pharmacology 74 (1), 41-53, 2007 | 56 | 2007 |
| The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties K Lemke, V Poindessous, A Skladanowski, AK Larsen Molecular pharmacology 66 (4), 1035-1042, 2004 | 55 | 2004 |
| Hyaluronic acid and phospholipid interactions useful for repaired articular cartilage surfaces—A mini review toward tribological surgical adjuvants S Jung, A Petelska, P Beldowski, WK Augé, T Casey, D Walczak, ... Colloid and polymer science 295, 403-412, 2017 | 33 | 2017 |
| Structural factors affecting affinity of cytotoxic oxathiole-fused chalcones toward tubulin MT Konieczny, A Buɬakowska, D Pirska, W Konieczny, A Skladanowski, ... European journal of medicinal chemistry 89, 733-742, 2015 | 30 | 2015 |
| Structural Factors Affecting Cytotoxic Activity of (E)‐1‐(Benzo[d ][1,3]oxathiol‐6‐yl)‐3‐phenylprop‐2‐en‐1‐one Derivatives MT Konieczny, A Bułakowska, J Polak, D Pirska, W Konieczny, P Gryń, ... Chemical biology & drug design 84 (1), 86-91, 2014 | 15 | 2014 |
| Pharmacokinetic studies of oxathio-heterocycle fused chalcones K Okoniewska, MT Konieczny, K Lemke, T Grabowski European journal of drug metabolism and pharmacokinetics 42, 49-58, 2017 | 10 | 2017 |
| Inhibition of DNA topoisomerase II by antitumor triazoloacridinones in vitro and in tumor cells A Składanowski, AK Larsen, J Konopa, K Lemke Proc Am Assoc Cancer Res 40, 681, 1999 | 9 | 1999 |
| Influence of S‐Oxidation on Cytotoxic Activity of Oxathiole‐Fused Chalcones MT Konieczny, A Buɬakowska, D Pirska, W Konieczny, A Skladanowski, ... Chemical Biology & Drug Design 88 (4), 519-533, 2016 | 7 | 2016 |
| Anticancer fusion protein comprising trail JS Pieczykolan, S Pawlak, B Zerek, KK Lemke US Patent 9,102,759, 2015 | 5 | 2015 |
| Novel chalcone derivatives with cytotoxic activity M Konieczny, A Skladanowski, K Lemke, J Pieczykolan WO2011009826, 2011 | 3 | 2011 |
| Anticancer fusion protein comprising TRAIL and interferon JS Pieczykolan, KK Lemke, S Pawlak, B Żerek US Patent 9,161,991, 2015 | 2 | 2015 |
| Topoisomerases and transcriptional regulation AK Larsen, K Lemke, V Oestergaard, AH Andersen, A Vekris, MC Haaz, ... Eur. J. Cancer 38 (suppl), S71, 2002 | 2 | 2002 |
| Irofulven-resistant colon carcinoma cells show little or no cross-resistance with several anticancer drug types. F Koeppel, V Poindessous, K Lemke, A Skladanowski, E Raymond, ... CLINICAL CANCER RESEARCH 7 (11), 3696S-3696S, 2001 | 2 | 2001 |
| Heme oxygenase-1 inhibits murine myoblast differentiation and may induce tumor development M Kozakowska, A Stefanska, M Ciesla, K Skrzypek, H Was, A Jazwa, ... Vascular Pharmacology 5 (56), 311-312, 2012 | 1 | 2012 |
| Role of mirnas in heme oxygenase-1 mediated impairment of myoblast differentiation M Ciesla, M Kozakowska, K Skrzypek, A Stefańska, A Loboda, A Jazwa, ... Circulation 122 (suppl_21), A20095-A20095, 2010 | 1 | 2010 |
| Interaction of antitumor triazoloacridone C-1305 and its analogs with telomeric DNA J Olewniak, K Lemke, M Wojciechowski, A Składanowski Acta Biochimica Polonica 53, 157-158, 2006 | 1 | 2006 |
| Heme oxygenase-1 inhibits microRNA biogenesis and impairs myogenesis M Ciesla, M Kozakowska, A Stefanska, K Skrzypek, H Was, A Jazwa, ... Vascular Pharmacology 5 (56), 331, 2012 | | 2012 |
| European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress 2011 October 27–31, 2011 The Brighton Centre, Brighton United Kingdom LW Seymour, M Antoniou, DRP Harbottle, C Denning, R Hajjar, S Ferber, ... Human Gene Therapy, A1-A138, 2011 | | 2011 |
